Abstract | BACKGROUND: HYPOTHESIS: METHODS: Following exposure of the fetal head and chest at 123±1 day gestational age and with placental circulation intact, fetal lambs (n = 4-6/group) were randomized to either: 1) Gefitinib 15 mg IV and 1 mg intra-tracheal or 2) saline IV and IT. Lambs were further assigned to 15 minutes of either: a) Injurious mechanical ventilation (MV) or b) Continuous positive airway pressure (CPAP) 5 cmH2O. After the 15 minute intervention, the animals were returned to the uterus and delivered after i) 6 or ii) 24 hours in utero. RESULTS: CONCLUSION:
|
Authors | T Brett Kothe, Emily Royse, Matthew W Kemp, Haruo Usuda, Masatoshi Saito, Gabrielle C Musk, Alan H Jobe, Noah H Hillman |
Journal | PloS one
(PLoS One)
Vol. 13
Issue 7
Pg. e0200713
( 2018)
ISSN: 1932-6203 [Electronic] United States |
PMID | 30005089
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- EGF Family of Proteins
- Protein Kinase Inhibitors
- ErbB Receptors
- Gefitinib
|
Topics |
- Animals
- Bronchopulmonary Dysplasia
(pathology)
- Cell Proliferation
(drug effects)
- Disease Models, Animal
- EGF Family of Proteins
(metabolism)
- Epithelial Cells
(drug effects, pathology)
- ErbB Receptors
(antagonists & inhibitors, physiology)
- Female
- Fetal Development
(drug effects)
- Gefitinib
(pharmacology, therapeutic use)
- Humans
- Lung
(cytology, growth & development, pathology)
- Pregnancy
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Respiration, Artificial
(adverse effects)
- Sheep, Domestic
- Treatment Outcome
|